Melissa A. Edwards
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Melissa A. Edwards has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Dillon K. Jarrell
Department of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
2 shared publications - Haley Oana Tucker
Department of Molecular Biosciences, the University of Texas at Austin, 1 University Station A5000, Austin, TX 78712, USA
2 shared publications - Ilham M. Alshiraihi
Cell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523, USA
2 shared publications - Mark A. Brown
Cell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523, USA
2 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by MDPI AG in Veterinary Sciences
- Vol. 13 (9) , 966
RETRACTED: Edwards et al. The Lysine Methyltransferase SMYD2 Is Required for Definite Hematopoietic Stem Cell Production in the Mouse Embryo. Vet. Sci. 2020, 7, 100
The journal retracts the article titled “The Lysine Methyltransferase SMYD2 Is Required for Definite Hematopoietic Stem Cell Production in the Mouse Embryo”
- 15 September 2026
- Published by MDPI AG in Veterinary Sciences
- Vol. 13 (9) , 966
Open AccessRETRACTED: Edwards et al. The Lysine Methyltransferase SMYD2 Is Required for Definite Hematopoietic Stem Cell Production in the Mouse Embryo. Vet. Sci. 2020, 7, 100
The journal retracts the article titled “The Lysine Methyltransferase SMYD2 Is Required for Definite Hematopoietic Stem Cell Production in the Mouse Embryo”
- Open Access
- 25 July 2020
- Published by MDPI AG in Veterinary Sciences
- Vol. 7 (3) , 100
RETRACTED: The Lysine Methyltransferase SMYD2 Is Required for Definite Hematopoietic Stem Cell Production in the Mouse Embryo
The five-membered SET and MYND domain-containing lysine methyltransferase (SMYD) family plays pivotal roles in development and differentiation. Initially characterized within the cardiovascular system, one such member, SMYD2, has been implicated in transcriptional and apoptotic regulation of hematopoiesis. Deletion of Smyd2 in adult mouse Hemaopoietic Stem Cells (HSC) using an interferon-inducible mx1-Cre-mediated conditional knockout (CKO) led to HSC reduction via both apoptosis and transcriptional deficiencies. Since HSC are specified from hemogenic endothelial (HE) cells in the dorsal aorta (DA), we sought to determine whether the flaw in HSC originated embryologically from this site. Toward this end, we performed deletion with vav-Cre mice, which is active in all hematopoietic and endothelial tissues from E10.5 embryonic life onward. Unexpectedly, we observed no defects in the embryo, other than apoptotic loss of definite HSC, whereas adult hematopoietic populations downstream were unaffected. These results further establish the importance of SMYD2 in antiapoptotic gene control of gene expression from the embryo to the adult.
- 25 July 2020
- Published by MDPI AG in Veterinary Sciences
- Vol. 7 (3) , 100
Open AccessRETRACTED: The Lysine Methyltransferase SMYD2 Is Required for Definite Hematopoietic Stem Cell Production in the Mouse Embryo
The five-membered SET and MYND domain-containing lysine methyltransferase (SMYD) family plays pivotal roles in development and differentiation. Initially characterized within the cardiovascular system, one such member, SMYD2, has been implicated in transcriptional and apoptotic regulation of hematopoiesis. Deletion of Smyd2 in adult mouse Hemaopoietic Stem Cells (HSC) using an interferon-inducible mx1-Cre-mediated conditional knockout (CKO) led to HSC reduction via both apoptosis and transcriptional deficiencies. Since HSC are specified from hemogenic endothelial (HE) cells in the dorsal aorta (DA), we sought to determine whether the flaw in HSC originated embryologically from this site. Toward this end, we performed deletion with vav-Cre mice, which is active in all hematopoietic and endothelial tissues from E10.5 embryonic life onward. Unexpectedly, we observed no defects in the embryo, other than apoptotic loss of definite HSC, whereas adult hematopoietic populations downstream were unaffected. These results further establish the importance of SMYD2 in antiapoptotic gene control of gene expression from the embryo to the adult.